APOLLO Oncology Clinical Trials Program

APOLLO Oncology Clinical Trials Program

The APOLLO Oncology Clinical Trials Program is a series of trials evaluating and investigating whether Apollomics’ c-Met inhibitor can work in concert with other agents to improve on single agent outcomes. Multiple combination trials are being initiated and/or planned with our c-Met inhibitor.


APOLLO is a Phase 1/2, open label, two-arm, multi-center dose escalation and expansion study targeting locally advanced or metastatic disease.
clinicaltrials.gov: NCT03655613

Agents:           APL-101 (c-Met inhibitor) + APL-501 (anti-PD-1)
Indication:       Hepatocellular Carcinoma

Agents:           APL-101 (c-Met inhibitor) + nivolumab (anti-PD-1)
Indication:       Renal Cell Carcinoma

APOLLO-2 Trial

APOLLO-2 is a planned clinical trial combining APL-101 plus an approved immunotherapy with or without chemotherapy.

Agents:           APL-101 (c-Met inhibitor) + I/O +/- Chemotherapy
Indication:       NSCLC

Posters & Publications

Posters and Publications on our assets can be found here.